Astaxanthin review reports biomarker changes, with clinical benefits still difficult to judge
Human studies reported lower inflammation and oxidative-stress markers, but the abstract gives no effect sizes, treatment comparisons or follow-up lengths.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reports favorable changes in markers of inflammation, oxidative stress and antioxidant capacity after astaxanthin supplementation. It also describes outcomes in studies combining the supplement with exercise and in selected clinical groups. The abstract does not show how large these changes were or establish broad clinical benefits from astaxanthin alone.
This abstract-based summary lacks study-level designs, participant totals, doses, comparators and effect estimates. Safety results are not described. These omissions limit assessment of how convincing, clinically meaningful or broadly applicable the reported findings are.
Markers and health outcomes
Several reported outcomes were laboratory measures rather than symptoms or health events. Changes in these markers do not, by themselves, demonstrate that people feel better or avoid disease, even when the direction appears favorable.
Different interventions and populations
Some studies paired astaxanthin with exercise, while others examined women with PCOS or endometriosis. The abstract reports reproductive-cell outcomes in those groups, which should not be presented as proof of improved pregnancy or birth outcomes.
The original publication
The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review.
Malcangi G, Inchingolo AM, Casamassima L et al.
Int J Mol Sci · 2026
- PubMed ID
- 41596351
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.